Skip to main content

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL

Conference Correspondent - ASH 2018 - Chronic Lymphocytic Leukemia

At the ASH 2018 Annual Meeting, researchers reported up to 7 years of follow-up data for patients receiving single-agent ibrutinib in the first-line and relapsed/refractory (R/R) settings.

Of the 132 patients followed in the PCYC-1103 extension study, 31 received first-line ibrutinib and 101 had R/R disease. As of the latest data cutoff, 17 (55%) first-line and 21 (21%) R/R patients have continued ibrutinib treatment, with median follow-up of 67 months. Median age for all patients was 71 (first line) and 64 (R/R) years and 57% of patients were younger than 70 years of age (first line, 74%; R/R, 34%). More than one-half of patients have unmutated IGHV (first line, 48%; R/R, 78%).

With up to 7 years of follow-up, sustained activity of single-agent ibrutinib was seen in both first-line and R/R patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, including those with high-risk genomic factors. In the analysis, the overall response rate was 89% for all patients, with similar rates in first-line (87% [complete response (CR), 32%]) and R/R (89% [CR, 10%]) patients. Median progression-free survival (PFS) was not reached for first-line patients and was 51 months for R/R patients. Estimated 6-year PFS rates were 88% and 37%, respectively. Median overall survival (OS) was not reached in either first-line or R/R patients, and estimated 6-year OS rates were 88% and 58%, respectively. Median PFS and 6-year PFS estimates were impressive in R/R patients with high-risk characteristics:

Table 1

Grade ≥3 adverse events (AEs) were reported in fewer first-line (74%) patients than R/R (89%) patients, despite longer median time on treatment for first-line patients (72 months vs 39 months). Grade ≥3 AEs occurring more frequently among first-line patients included hypertension (32%), diarrhea (16%), and hyponatremia (10%); grade ≥3 AEs occurring more frequently among R/R patients were pneumonia (27%), neutropenia (21%), thrombocytopenia (11%), and cellulitis (9%). Grade ≥3 infections occurred in 23% of first-line patients and in 55% of R/R patients. Fatal AEs occurred in 6% of first-line and 17% of R/R patients. Overall, the number of serious AEs decreased over time.

Overall, ibrutinib responses were durable, with sustained PFS and OS rates in both first-line and R/R patients. In R/R CLL, ibrutinib administration in earlier lines of therapy resulted in improved PFS outcomes. Tolerability was similar to previous reports, and most grade ≥3 AEs declined over time.

Byrd JC, et al. ASH 2018. Abstract 3133.

Related Items
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL
Conference Correspondent published on December 2, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Last modified: August 30, 2021